RxDoctor Payments Data

Laura Zitella

Nurse Practitioner · San Francisco, CANPI 1265570949

Payments from drug & device makers

$8,406in general payments, 2019–2025

Across 27 payments — averaging $311.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Beigene USA, Inc.$1K
  • Pfizer$1K
  • Johnson & Johnson$413
  • Sanofi$109
  • plus $388 from 7 others

What the payments were for

  • Consulting fees$5,92570%
  • Speaking & faculty fees$1,00012%
  • Food & beverage$1,35816%
  • Education$1231%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,406 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$86,432
Medicare patients
206
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib42$553,798
ImbruvicaIbrutinib31$489,351
EliquisApixaban14$18,335
Atovaquone23$13,446
Entecavir13$6,306
ValacyclovirValacyclovir Hcl54$2,789
Acyclovir70$2,173
Gabapentin25$329
Ondansetron Hcl13$317
Famotidine16$281
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim33$215
Allopurinol19$158
Trazodone Hcl11$114
Prednisone21$78
Levofloxacin11$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$1,307$553,79842 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$47$489,35131 claims
PfizerEliquis$1,050$18,33514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →